Kolitis adalah salah satu penyakit saluran cerna yang sering dijumpai di Indonesia. Peptida antimikroba human beta-defensin 2 (hBD-2) merupakan bagian dari komponen sistem imun alamiah sistem gastrointestinal yang diteliti perannya dalam patofisiologi kolitis. Penelitian ini bertujuan memperoleh kadar hBD-2 feses pada pasien kolitis di RSUPN dr. Cipto Mangunkusumo, serta apakah terdapat perbedaan kadarnya pada kolitis infeksi dan non-infeksi. Penelitian potong lintang ini dilakukan pada subjek kolitis yang direkrut secara konsekutif di poliklinik Gastroenterologi dan Pusat Endoskopi Saluran Cerna RSUPN dr. Cipto Mangunkusumo, pada bulan Juni – Oktober 2020. Sampel feses dari subjek diperiksakan kadar hBD-2 dengan metode ELISA, feses rutin, darah samar, serta biakan di Laboratorium Departemen Patologi Klinik RSUPN dr. Cipto Mangunkusumo. Kadar hBD-2 feses subjek kolitis infeksi dibandingkan dengan kadar hBD-2 feses subjek kolitis non-infeksi. Diperoleh 26 subjek kolitis infeksi dan 20 subjek kolitis non-infeksi dengan median kadar hBD-2 feses berturut-turut adalah 40,39 (5,11 – 555,27) ng/ml dan 36,35 (1,75 – 260,34) ng/ml. Terdapat kecenderungan kadar hBD-2 feses yang tinggi pada subjek kolitis tuberkulosis dan kolitis jamur dengan median berturut-turut 460,55 (30,94 – 555,27) ng/ml dan 340,45 (283,01 – 361,95) ng/ml. Tidak terdapat perbedaan kadar hBD-2 feses yang bermakna antara kolitis infeksi dan non-infeksi (p > 0,05). Perlu dilakukan penelitian lanjutan dengan jumlah subjek lebih banyak untuk kelompok kolitis tuberkulosis dan kolitis jamur.

---

Colitis is one of the most common gastrointestinal diseases in Indonesia. Antimicrobial peptide human beta-defensin 2 (hBD-2) is a part of gastrointestinal innate immunity which roles in the pathophysiology of colitis are still being studied. This study aims to determine fecal hBD-2 concentration in colitis at RSUPN dr. Cipto Mangunkusumo, and whether there is significant difference of its concentration in infective and non-infective colitis. A cross-sectional study was conducted on colitis subjects recruited consecutively at Gastroenterology Clinic and Gastroenterology Endoscopy Center of RSUPN dr. Cipto Mangunkusumo, in June - October 2020. Stool samples collected were tested for hBD-2 concentration using ELISA method, routine fecal analysis, fecal occult blood test, and culture at Clinical Pathology Laboratory of RSUPN dr. Cipto Mangunkusumo. Fecal hBD-2 concentration was compared between infective and non-infective colitis. There were 26 subjects with infective colitis and 20 subjects with non-infective colitis. Fecal hBD-2 concentrations of the two groups were 40,39 (5,11 – 555,27) ng/ml and 36,35 (1,75 – 260,34) ng/ml. Fecal hBD-2 concentrations in tuberculous colitis and fungal colitis tended to be high, 460,55 (30,94 – 555,27) ng/ml and 340,45 (283,01 – 361,95) ng/ml. There was no significant difference of fecal hBD-2 concentrations in infective and non-infective colitis (p > 0,05). It is recommended to conduct further study with more subjects regarding group tuberculous colitis and fungal colitis.